"10.1371_journal.pone.0064969","plos one","2013-05-21T00:00:00Z","Colleen E Albacker; Narie Y Storer; Erin M Langdon; Anthony DiBiase; Yi Zhou; David M Langenau; Leonard I Zon","Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts, United States of America; Department of Pathology, Massachusetts General Hospital, Harvard Stem Cell Institute, Charlestown, Massachusetts, United States of America","Conceived and designed the experiments: CEA NYS DML LIZ. Performed the experiments: CEA NYS EML. Analyzed the data: CEA NYS AD YZ DML LIZ. Contributed reagents/materials/analysis tools: CEA NYS AD YZ DML. Wrote the paper: CEA LIZ.","The authors have the following interests: Len Zon is a founder and stockholder of Fate, Inc. and a scientific advisor for Stemgent. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","05","Colleen E Albacker","CEA",7,TRUE,4,3,6,2,TRUE,TRUE,FALSE,0,NA,FALSE
